Volume 64, Issue 6, Pages (December 2003)

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

Acid-base profile in patients on PD
Volume 79, Pages S3-S8 (April 2011)
Volume 54, Issue 2, Pages (August 1998)
Volume 67, Pages S1-S7 (June 2005)
FGF-23 in patients with end-stage renal disease on hemodialysis
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Volume 73, Issue 1, Pages 3-5 (January 2008)
Volume 89, Issue 4, Pages (April 2016)
Acid-base profile in patients on PD
Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis  James F. Medcalf, Kevin P.G.
Volume 83, Issue 3, Pages (March 2013)
FGF23 or PTH: which comes first in CKD ?
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Volume 55, Issue 2, Pages (February 1999)
Figure 4 Model of changes in the serum levels
Volume 78, Issue 10, Pages (November 2010)
FGF23–parathyroid interaction: implications in chronic kidney disease
Volume 79, Pages S24-S27 (April 2011)
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Haiyan Wang, Luxia Zhang, Jicheng Lv  Kidney International 
Expression of inter-α-trypsin inhibitor and tumor necrosis factor-stimulated gene 6 in renal proximal tubular epithelial cells  Ulf Janssen, Gareth Thomas,
Volume 60, Issue 4, Pages (October 2001)
Down-regulation of Na+ transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia  Lúcia Andrade, Nancy A. Rebouças, Antonio.
Volume 70, Issue 11, Pages (December 2006)
Volume 79, Pages S20-S23 (April 2011)
Magnus Åbrink, Eric Larsson, Anders Gobl, Lars Hellman 
Use of vitamin D in chronic kidney disease patients
Florian Lang, Michael Föller  Kidney International 
Plasma FGF23 levels increase rapidly after acute kidney injury
Clinical relevance of FGF-23 in chronic kidney disease
Volume 69, Issue 3, Pages (February 2006)
Volume 70, Issue 12, Pages (December 2006)
Volume 79, Issue 2, Pages (January 2011)
Volume 68, Pages S24-S28 (July 2005)
FGF-23 in patients with end-stage renal disease on hemodialysis
Volume 70, Issue 12, Pages (December 2006)
Volume 56, Pages S31-S37 (December 1999)
P. Urena Torres, G. Friedlander, M.C. de Vernejoul, C. Silve, D. Prié 
Volume 87, Issue 3, Pages (March 2015)
Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function  S.L.S. Fan, T. Pile, S. Punzalan, M.J.
Volume 68, Issue 3, Pages (September 2005)
Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease  Shen Xiao, Laszlo Wagner, Rebecca J. Schmidt,
Fibroblast growth factor 23: the making of a hormone
Volume 79, Issue 12, Pages (June 2011)
Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita  Kidney International 
Post-transplant hypophosphatemia: Tertiary ‘Hyper-Phosphatoninism’?
Volume 56, Issue 3, Pages (September 1999)
Volume 71, Issue 8, Pages (April 2007)
Volume 78, Issue 10, Pages (November 2010)
Pablo A. Ureña Torres, Marc De Broe  Kidney International 
Volume 82, Issue 10, Pages (November 2012)
Volume 80, Issue 10, Pages (November 2011)
Increased parathyroid expression of klotho in uremic rats
Volume 64, Issue 1, Pages (July 2003)
Recent developments in the management of secondary hyperparathyroidism
Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease  Aquiles Jara, Arnold J. Felsenfeld, Jordi.
Volume 54, Issue 6, Pages (January 1998)
The ins and outs of phosphate homeostasis
Volume 53, Issue 5, Pages (May 1998)
Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).
Marta Christov, Harald Jüppner  Kidney International 
Volume 83, Issue 1, Pages (January 2013)
Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases  Martina Franz, Wolfgang Woloszczuk,
Tamara Isakova, Orlando M. Gutiérrez, Myles Wolf  Kidney International 
Volume 56, Issue 6, Pages (December 1999)
Ronen Levi, Justin Silver  Kidney International 
Volume 86, Issue 2, Pages (August 2014)
Presentation transcript:

Volume 64, Issue 6, Pages 2272-2279 (December 2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers  Tobias Larsson, U.L.F. Nisbeth, Östen Ljunggren, Harald Jüppner, Kenneth B. Jonsson  Kidney International  Volume 64, Issue 6, Pages 2272-2279 (December 2003) DOI: 10.1046/j.1523-1755.2003.00328.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 The serum values of the three separate groups. (A) Creatinine (umol/L). (B) Fibroblast growth factor-23 (FGF-23) (RU/mL). Note that scales are logarithmic. (C) Phosphate (mmol/L). (D) Calcium (mmol/L). (E) Parathyroid hormone (PTH) (ng/L). (F) 1,25(OH)2D3 (ng/L). Abbreviations are: D, dialysis group; PD, predialysis group; T, transplant group. The boxes represent the mean ± SEM and the vertical lines the maximum and minimum values in the population measured. Kidney International 2003 64, 2272-2279DOI: (10.1046/j.1523-1755.2003.00328.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 The correlation for entire population of 83 patients with varying stages of renal disease between the log fibroblast growth factor-23 (FGF-23) serum concentration and creatinine (A) or phosphate (B). Kidney International 2003 64, 2272-2279DOI: (10.1046/j.1523-1755.2003.00328.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Western blot analysis using urine from a dialysis patient with some residual renal function (lane 1) and a healthy volunteer (lane 2) after immunoprecipitation with rabbit anti-[Tyr-224] FGF-23(225–244) amide antibody. Using the same anti-[Tyr-224] FGF-23(225–244) amide antibody, a ≈32 kD band and several other protein bands of lower molecular weight were readily detected in urine from chronic kidney disease (CKD) patients; these bands were only faint when urine from the normal volunteer was immunoprecipitated. When the antibody for detection was preincubated with excessive amount of peptide that was used for immunization, none of these protein bands was detected (lane 3). Lanes 4 and 5 displays serum after immunoprecipitation from a CKD patient and a healthy volunteer, respectively. Only a ≈32 kD band was detected in both lanes, although much weaker in the healthy volunteer. Kidney International 2003 64, 2272-2279DOI: (10.1046/j.1523-1755.2003.00328.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Serum and urine biochemical parameters measured during the phosphate deprivation/loading experiment in six healthy volunteers marked as P1 to P6. (A) Fibroblast growth factor-23 (FGF-23) (RU/mL). (B) u-FGF-23 (RU/mL). (C) Phosphate (mmol/L). (D) Total amount of phosphate (TPR) (%). (E) Parathyroid hormone (PTH) (ng/L). (F) 1,25(OH)2D3 (ng/L). FGF-23 and phosphate were measured at 8:00 a.m., 12:00 a.m., 4:00 p.m., and 8:00 p.m. throughout the experiment. u-FGF-23, %TPR, PTH, and 1,25(OH)2D3 were measured every day at 8:00 a.m. The hours 0 to 24 represent the calibration period; hours 24 to 72, the phosphate deprivation phase; and hours 72 to 144, the phosphate loading phase. The dashed vertical lines indicate the time at which phosphate deprivation and phosphate loading, respectively, was started. The hatched areas represent the adult normal ranges for the different parameters. Kidney International 2003 64, 2272-2279DOI: (10.1046/j.1523-1755.2003.00328.x) Copyright © 2003 International Society of Nephrology Terms and Conditions